Clostridium difficile infection is associated with poor outcomes in end-stage renal disease
- PMID: 22222233
- DOI: 10.2310/JIM.0b013e318242b313
Clostridium difficile infection is associated with poor outcomes in end-stage renal disease
Abstract
Objective: To investigate the association of Clostridium difficile infection (CDI) with the outcomes of hospitalized patients with end-stage renal disease (ESRD).
Methods: We extracted all adult cases with a discharge diagnosis of ESRD or CDI from the United States Nationwide Inpatient Sample 2009 database. Outcome variables (mortality, length of hospital stay [LOS], and hospitalization charges), demographic information, and comorbidity data were collected. Data were evaluated by univariate and multiple regression analyses.
Results: We identified 184,139 cases with ESRD of which 2.8% had CDI. Comparison of patients with ESRD + CDI to those with only ESRD revealed in-hospital mortality (13.2% vs 5.3%; P < 0.001), LOS (17.3 vs 7.1 days; P < 0.001), and charges ($124,846 vs $56,663; P < 0.001) to be more than 2-fold greater. In the ESRD cohort (ESRD only and ESRD + CDI), CDI was independently associated with greater mortality (adjusted odds ratio, 2.15; 95% CI, 2.07-2.24; P < 0.001), longer LOS (mean difference, 9.4 days; 95% CI, 9.2-9.5; P < 0.001), and higher charges (mean difference, $62,824; 95% CI, 61,615-64,033; P < 0.001).
Conclusions: Clostridium difficile infection is associated with significantly worse outcomes in hospitalized patients with ESRD.
Similar articles
-
Association of Clostridium difficile infection with outcomes of hospitalized solid organ transplant recipients: results from the 2009 Nationwide Inpatient Sample database.Transpl Infect Dis. 2012 Oct;14(5):540-7. doi: 10.1111/j.1399-3062.2012.00761.x. Epub 2012 Jun 22. Transpl Infect Dis. 2012. PMID: 22726461
-
The burden of Clostridium difficile in surgical patients in the United States.Surg Infect (Larchmt). 2007 Dec;8(6):557-66. doi: 10.1089/sur.2006.062. Surg Infect (Larchmt). 2007. PMID: 18171114
-
Impact of end stage kidney disease on costs and outcomes of Clostridium difficile infection.Int J Infect Dis. 2017 Sep;62:8-9. doi: 10.1016/j.ijid.2017.06.013. Epub 2017 Jun 20. Int J Infect Dis. 2017. PMID: 28645569
-
Chronic kidney disease and end-stage renal disease are risk factors for poor outcomes of Clostridium difficile infection: a systematic review and meta-analysis.Int J Clin Pract. 2015 Sep;69(9):998-1006. doi: 10.1111/ijcp.12672. Epub 2015 Jul 5. Int J Clin Pract. 2015. PMID: 26147121 Free PMC article. Review.
-
Hospitalization stay and costs attributable to Clostridium difficile infection: a critical review.J Hosp Infect. 2014 Sep;88(1):12-21. doi: 10.1016/j.jhin.2014.04.011. Epub 2014 May 17. J Hosp Infect. 2014. PMID: 24996516 Review.
Cited by
-
Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI.Infect Dis Ther. 2024 Oct;13(10):2105-2121. doi: 10.1007/s40121-024-01007-z. Epub 2024 Jun 28. Infect Dis Ther. 2024. PMID: 38941068 Free PMC article.
-
Prevalence of Comorbid Factors in Patients With Recurrent Clostridioides difficile Infection in ECOSPOR III, a Randomized Trial of an Oral Microbiota-Based Therapeutic.Clin Infect Dis. 2023 Nov 30;77(11):1504-1510. doi: 10.1093/cid/ciad448. Clin Infect Dis. 2023. PMID: 37539715 Free PMC article. Clinical Trial.
-
Clostridioides difficile Infection in an Italian Tertiary Care University Hospital: A Retrospective Analysis.Antibiotics (Basel). 2023 Apr 30;12(5):837. doi: 10.3390/antibiotics12050837. Antibiotics (Basel). 2023. PMID: 37237740 Free PMC article.
-
Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent Clostridioides difficile Infection: A Phase 3, Open-Label, Single-Arm Trial.JAMA Netw Open. 2023 Feb 1;6(2):e2255758. doi: 10.1001/jamanetworkopen.2022.55758. JAMA Netw Open. 2023. PMID: 36780159 Free PMC article. Clinical Trial.
-
Clinical Determinants Predicting Clostridioides difficile Infection among Patients with Chronic Kidney Disease.Antibiotics (Basel). 2022 Jun 8;11(6):785. doi: 10.3390/antibiotics11060785. Antibiotics (Basel). 2022. PMID: 35740191 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
